eShowcase: Oracle Remote Data Capture Onsite
New data entry interface runs on top of existing software for accelerated navigation
New data entry interface runs on top of existing software for accelerated navigation
Oracle Corp. (Redwood Shores, CA) introduced Remote Data Capture Onsite, its next-generation EDC system data collection for clinical trial investigative sites. The interface is designed to accelerate and simplify the collection of clinical data and EDC deployment at investigative sites.
The new Oracle interface runs on top of its existing software product Oracle Remote Data Capture v4.5.1 for more intuitive data entry and navigation of CRFs. The interface allows site personnel to easily locate and update patient information and data entry, as well as add pages to the CRF. The system performs immediate online edit checks, which involves a discrepancy management module from the CRF to capture, route, and resolve discrepancies if applicable.
The Onsite interface features graphic icons that illustrate the status of CRF data. It also enables electronic messaging between users, CRF verifications as a group or individually, and backup approvals with e-signatures.
Oracle Corp., (650) 506-8920, www.oracle.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
